article thumbnail

Evive, Acrotech get FDA nod for Ryzneuta (Efbemalenograstim alfa Injection) for chemo-induced neutropenia

Express Pharma

It helps to enhance the immune function of cancer patients and prevent the side effects of neutropenia caused by chemotherapy. Due to its unique molecular structure, Ryzneuta may possess stronger GCSF receptor activation properties and avoid the potential problem (such as allergic reactions) caused by PEG or Tween-80.

article thumbnail

US FDA approves Apellis’ geographic atrophy therapy Syfovre

Pharmaceutical Technology

It provides comprehensive control of the complement cascade, which is part of the immune system of the body, by targeting C3. Vitreous floaters, ocular discomfort, conjunctival hemorrhage, and neovascular AMD were the most common adverse reactions observed in patients receiving Syfovre.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Health Canada approves Arcutis Biotherapeutics’ Zoryve for Plaque Psoriasis

Pharmaceutical Business Review

Insomnia, upper respiratory tract infection, headache, application site pain, urinary tract infection, nausea, and diarrhea are the most common adverse reactions. We are proud to bring this important new steroid-free cream to Canada, where there is a need for safe and effective topical treatment for plaque psoriasis.

article thumbnail

Non-vaccine nasal spray could protect against COVID-19

pharmaphorum

That could be important if it takes longer than expected to bring vaccines and antibodies to market, said a spokesman for the companies, pointing to the news this week that AstraZeneca has halted phase 3 trials of its COVID-19 vaccine candidate AZD1222 after a serious adverse reaction in one patient.

Vaccines 133
article thumbnail

Magenta Therapeutics Pauses the P-I/II Study in AML Patients

PharmaShots

Ref: GlobeNewswire | Image: Magenta Therapeutics Related News:- AC Immune Reports Results of ACI-24.060 in P-Ib/II Trial for the Treatment of Alzheimer’s Disease and Down Syndrome Shots: The participant from the P-I/II dose-escalation, study dosed MGTA-117 at the Cohort 3 level (0.08

article thumbnail

FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel

pharmaphorum

The most common adverse reactions seen in a trial cohort of 38,000 patients were at injection sites (84.1%) followed by fatigue (62.9%) and headache (55.1%), and serious adverse reactions occurred in 0% to 4.6% of participants.

Vaccines 110
article thumbnail

FDA approves first gene therapy for high-risk early bladder cancer

European Pharmaceutical Review

The most common adverse reactions (ARs) included bladder discharge, fatigue, bladder spasm, urinary urgency, haematuria (presence of blood in urine), chills, fever, and painful urination. The FDA stated that individuals who are immunosuppressed, or immune-deficient should not come into contact with Adstiladrin.